Renal protection in the patients with idiopathic hypertensia: the possibilities of the combined blockade of the renin-angiotensin-aldosteron system


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Reninangiotensinaldosterone system is a key link in regulation of blood pressure and causes the target organ damage in hypertensive patients. For many years is not lost interest in the pharmacological blockade of RAAS in order to achieve target levels of BP and prevent damage target organs, particularly kidneys. Most recently recommended for clinical application of direct rennin inhibitor - aliskiren, a number of reseaeches have proven expressed nephroprotective effect. However, at present there is no unequivocal answer to the question whether there are advantages in combined RAAS blockade in hypertensive patients with use of aliskiren and angiotensinconverting enzyme inhibitor or angiotensin receptor blocker.

全文:

受限制的访问

参考

  1. Чазова И.Е., Ратова Л.Г. Артериальная гипертония, курение, почки - что общего? // Справочник поликлинического врача. - 2008. - № 10. - С. 14-17.
  2. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации // Рос. кардиол. журн. - 2006. - № 4. - С. 45-50.
  3. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design // Nephrol. Dial. Transplant. - 2009, Jan. 14. [Epub ahead of print] 1 of 9.
  4. Boehm M., Nabel E.G. Angiotensin-Converting Enzyme 2 - A New Cardiac Regulator // N. Engl. J. Med. - 2002. - Vol. 347. - P. 1795-1797.
  5. Dogrell S.A. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease // Lancet. - 2003. -Vol. 361. - Р. 117-124.
  6. Goodfriend Т.Ь. Angiotensins: actions and receptors. In Hypertension S.Oparil, M.Weber. -2000. - P. 11-13.
  7. Joshi S.R. et al. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial) // J. Assoc. Physicians India. - 2004. - Vol. 52. -P. 189-195.
  8. Mogensen C.E. et al. Randomised controlled trial of dual blockade of renin- angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Brit. Med. J. - 2000. - Vol. 321. - P. 1440-1444.
  9. Parving H.H., Persson F., Lewis J.B. et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2008, Jun. 5. - Vol. 358, N 23. - Р. 2433-2446.
  10. Rene R. Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease // Current. Drug. Therapy. - 2006. - Vol. 1. - P. 47-54.
  11. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors / Eduardo Pimenta and Suzanne Oparil // Vasc. Health Risk. Manag. - 2009. - N 5. - Р. 453-463.
  12. Yusuf S. et al. For the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - Vol. 358. - Р. 1547-1559.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Kachnov V.A., Tyrenko V.V., Nikitin A.E., Sinopalnikov D.O., Koltsov A.V., 2010


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: № 01975 от 30.12.1992.
##common.cookie##